newsfilter
← Latest News
PR Newswire·

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

New late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing